Journal of Medicinal Chemistry
Article
cancer cells but not in normal fibroblasts. Neoplasia 2007, 9, 766−776.
7050. (b) Takai, N.; Ueda, T.; Nasu, K.; Yamashita, S.; Toyofuku, M.;
Narahara, H. Targeting calcium/calmodulin-dependence kinase I and
II as a potential anti-proliferation remedy for endometrial carcinomas.
Cancer Lett. 2009, 277, 235−243. (c) Han, Y. J.; Ma, S. F.; Yourek, G.;
Park, Y. D.; Garcia, J. G. A transcribed pseudogene of MYLK promotes
cell proliferation. FASEB J. 2011, 25, 2305−2312. (d) Horbelt, D.;
Denkis, A.; Knaus, P. A portrait of transforming growth factor beta
superfamily signaling: background matters. Int. J. Biochem. Cell Biol.
2012, 44, 469−474. (e) Wang, P.; Yu, J.; Yin, Q.; Li, W.; Ren, X.; Hao,
X. Rosiglitazone suppresses glioma cell growth and cell cycle by
blocking the transforming growth factor-beta mediated pathway.
Neurochem. Res. [Online early access]. DOI: 10.1007/s11064-012-
0828-8. Published Online: 2012. (f) Zoubeidi, A.; Rocha, J.; Zouanat,
F. Z.; Hamel, L.; Scarlata, E.; Aprikian, A. G.; Chevalier, S. The Fer
tyrosine kinase cooperates with interleukin-6 to activate signal
transducer and activator of transcription 3 and promote human
prostate cancer cell growth. Mol. Cancer Res. 2009, 7, 142−155.
(g) Wang, S. Y.; Li, F. F.; Zheng, H.; Yu, K. K.; Ni, F.; Yang, X. M.;
Qu, C. K.; Li, J. Rapid induction and activation of Tec tyrosine kinase
in liver regeneration. J. Gastroenterol. Hepatol. 2006, 21, 668−673.
(h) Feng, X.; Lu, X.; Man, X.; Zhou, W.; Jiang, L. Q.; Knyazev, P.; Lei,
L.; Huang, Q.; Ullrich, A.; Zhang, Z.; Chen, Z. Overexpression of Csk-
binding protein contributes to renal cell carcinogenesis. Oncogene
2009, 28, 3320−3331.
(19) Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero,
D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and analysis of
patterns of differential activity of drugs against human tumor cell lines:
development of mean graph and COMPARE algorithm. J. Natl. Cancer
Inst. 1989, 81, 1088−1092.
(20) Chan, J.; Khan, S. N.; Harvey, I.; Merrick, W.; Pelletier, J.
Eukaryotic protein synthesis inhibitors identified by comparison of
cytotoxicity profiles. RNA 2004, 10, 528−543.
(21) (a) Gharehbaghi, K.; Paul, K.; Kelley, J. J.; Barchi, J. J., Jr.;
Marquez, V. E.; Cooney, D. A.; Monks, A.; Scudiero, D.; Kohn, K.;
Jayaram, H. N. Cytotoxicity and characterization of an active
metabolite of benzamide ribosode: a novel inhibitor of IMP
dehydrogenase. J. Cancer 1994, 56, 892−899. (b) Cleaveland, E. S.;
Monks, A.; Vaigro-Wolff, A.; Zaharevitz, D. W.; Paull, K.; Ardalan, K.;
Cooney, D. A.; Ford, H., Jr. Site of action of two novel pyrimidine
biosynthesis inhibitors accurately predicted by the COMPARE
program. Biochem. Pharmacol. 1995, 49, 947−954. (c) Kohlhagen,
G.; Paull, K.; Cushman, M.; Nagafuji, P.; Pommier, Y. Protein-linked
DNA strand breaks induced by NSC314622: a novel non-
camptothecin topoisomerase I poison. Mol. Pharmacol. 1998, 54,
50−58. (d) Zaharevitz, D. W.; Gussio, R.; Loest, M.; Senderowicz, A.
M.; Lahusen, T.; Kunick, C.; Meijer, L.; Sausville, E. A. Discovery and
initial characterization of the paullones: a novel class of small-molecule
inhibitors of cyclin-dependent kinases. Cancer Res. 1999, 59, 2566−
2569.
̀
(b) Mathieu, V.; De Neve, N.; Le Mercier, M.; Dewelle, J.; Gaussin, J.
F.; Dehoux, M.; Kiss, R.; Lefranc, F. Combining bevacizumab with
temozolomide increases the antitumor efficacy of temozolomide in a
human glioblastoma orthotopic xenograft model. Neoplasia 2008, 10,
1383−1392. (c) Ingrassia, L.; Lefranc, F.; Dewelle, J.; Pottier, L.;
Mathieu, V.; Spiegl-Kreinecker, S.; Sauvage, S.; El Yazidi, M.; Dehoux,
M.; Berger, W.; Van Quaquebeke, E.; Kiss, R. Structure−activity
relationship analysis of novel derivatives of narciclasine (an
Amaryllidaceae isocarbostyril derivative) as potential anticancer agents.
J. Med. Chem. 2009, 52, 1100−1114. (d) Lamoral-Theys, D.; Andolfi,
A.; Van Goietsenoven, G.; Cimmino, A.; Le Calve,
́
B.; Wauthoz, N.;
Megalizzi, V.; Gras, T.; Bruyere, C.; Dubois, J.; Mathieu, V.;
́
̀
Kornienko, A.; Kiss, R.; Evidente, A. Lycorine, the main phenan-
thridine Amaryllidaceae alkaloid, exhibits significant antitumor activity
in cancer cells that display resistance to proapoptotic stimuli: an
investigation of structure−activity relationship and mechanistic insight.
J. Med. Chem. 2009, 52, 6244−6256.
(13) (a) Delbrouck, C.; Doyen, I.; Belot, N.; Decaestecker, C.;
Ghanooni, R.; de Lavareille, A.; Kaltner, H.; Choufani, G.; Danguy, A.;
Vandenhoven, G.; Gabius, H. J.; Hasid, S.; Kiss, R. Galectin-1 is
overexpressed in nasal polyps under budesonide and inhibits
eosinophil migration. Lab. Invest. 2002, 82, 147−158. (b) Lefranc,
F.; Mijatovic, T.; Mathieu, V.; Rorive, S.; Decaestecker, C.; Debeir, O.;
Brotchi, J.; Van Ham, P.; Salmon, I.; Kiss, R. Characterization of
gastrin-induced proangiogenic effects in vivo in orthotopic U373
experimental human glioblastomas and in vitro in human umbilical
vein endothelial cells. Clin. Cancer Res. 2004, 10, 8250−8265.
(c) Mathieu, V.; Pirker, C.; martin de Lasalle, E.; Vernier, M.;
̀
Mijatovic, T.; De Neve, N.; Gaussin, J. F.; Dehoux, M.; Lefranc, F.;
Berger, W.; Kiss, R. The sodium pump alpha-1 subunit: a disease
progression-related target for metastatic melanoma treatment. J. Cell.
Mol. Med. 2009, 13, 3960−3972. (d) Van Goietsenoven, G.; Hutton,
J.; Becker, J. P.; Lallemand, B.; Robert, F.; Lefranc, F.; Pirker, C.;
Vandenbussche, G.; Van Antwerpen, P.; Evidente, A.; Berger, W.;
́
Prevost, M.; Pelletier, J.; Kiss, R.; Kinzy, T. G.; Kornienko, A.;
Mathieu, V. Targeting of eEF1A with Anaryllidaceae isocarbostyrils as
a strategy to combat melanomas. FASEB J. 2010, 24, 4575−4584.
(14) Branle, F.; Lefranc, F.; Camby, I.; Jeuken, J.; Geurts-Moespot,
A.; Sprenger, S.; Sweep, F.; Kiss, R.; Salmon, I. Evaluation of the
efficiency of chemotherapy in in vivo orthtopic models of human
glioma cells with and without 1p19q deletions and in C6 rat
orthotopic allografts serving for the evaluation of surgery combined
with chemotherapy. Cancer 2002, 95, 641−655.
(15) Developmental Therapeutic Program, Division of Cancer
Treatment and Diagnosis, National Cancer Institute, Rockville, MD,
(16) (a) Larsson, J.; Gottfries, J.; Bohlin, L.; Backlund, A. Expanding
the ChemGPS chemical space with natural products. J. Nat. Prod.
2005, 68, 985−991. (b) Larsson, J.; Gottfries, J.; Muresan, S.;
Backlund, A. ChemGPS-NP: tuned for navigation in biologically
relevant chemical space. J. Nat. Prod. 2007, 70, 789−794. (c) Rosen, J.;
(22) Kupchan, S. M.; LaVoie, E. J.; Branfman, A. R.; Fei, B. Y.; Bright,
W. M.; Bryan, R. F. Phyllantocin, a novel bisabolane aglycone from the
antileukemic glycoside, phyllantoside. J. Am. Chem. Soc. 1977, 99,
3199−3201.
Lovgren, A.; Kogej, T.; Muresan, S.; Gottfries, J.; Backlund, A.
̈
ChemGPS-NPWeb: chemical space navigation online. J. Comput.-Aided
Mol. Des. 2009, 23, 253−259.
(23) Choi, H. C.; Song, P.; Xie, Z.; Wu, Y.; Xu, J.; Zhang, M.; Dong,
Y.; Wang, S.; Lau, K.; Zou, M. H. Reactive nitrogen species is required
for the activation of the AMP-activated protein kinase by statin in vivo.
J. Biol. Chem. 2008, 283, 20186−20197.
(17) (a) Belot, N.; Rorive, S.; Doyen, I.; Lefranc, F.; Bruyneel, E.;
Dedecker, R.; Micik, S.; Brotchi, J.; Decaestecker, C.; Salmon, I.; Kiss,
R.; Camby, I. Molecular characterization of cell substratum attach-
ments in human glial tumors relates to prognostic features. Glia 2001,
36, 375−390. (b) Sivasankaran, B.; Degen, M.; Ghaffari, A.; Hegi, M.
E.; Hamou, M. F.; Ionescu, M. C.; Zweifel, C.; Tolnay, M.; Wasner,
M.; Mergenthaler, S.; Miserez, A. R.; Kiss, R.; Lino, M. M.; Merlo, A.;
Chiquet-Ehrismann, R.; Boulay, J. L. Tenascin-C is a novel
RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer
Res. 2009, 69, 458−465.
(24) (a) Lamoral-Theys, D.; Pottier, L.; Kerff, F.; Dufrasne, F.;
Proutier
̀
e, F.; Wauthoz, N.; Neven, P.; Ingrassia, L.; Van Antwerpen,
e, J.;
P.; Lefranc, F.; Gelbcke, M.; Pirotte, B.; Kraus, J. L.; Nev
̀
Kornienko, A.; Kiss, R.; Dubois, J. Simple di- and trivanillates exhibit
cytostatic properties toward cancer cells resistant to pro-apoptotic
stimuli. Bioorg. Med. Chem. 2010, 18, 3823−3833. (b) Lamoral-Theys,
D.; Wauthoz, N.; Heffeter, P.; Mathieu, V.; Jungwirth, U.; Lefranc, F.;
̀
Neve, J.; Dubois, J.; Dufrasne, F.; Amighi, K.; Berger, W.; Gailly, P.;
(18) (a) Yang, B. F.; Xiao, C.; Roa, W. H.; Krammer, P. H.; Hao, C.
Calcium/calmodulin-dependent protein kinase II regulation of c-FLIP
expression and phosphorylation in modulation of Fas-mediated
signaling in malignant glioma cells. J. Biol. Chem. 2003, 278, 7043−
Kiss, R. Trivanillic polyphenols with anticancer cytostatic effects
through the targeting of multiple kinases and intracellular Ca2+ release.
J. Cell. Mol. Med. 2012, 16, 1421−1434.
L
dx.doi.org/10.1021/jm300542e | J. Med. Chem. XXXX, XXX, XXX−XXX